The ITD of the JM domain of FLT3 (FLT3-ITD) is the most frequent and significant driver of mutation for human AML patients; it demonstrates a high tumor burden and confers an unfavorable prognosis [23, 25, 26]. The gene discussed is FLT3; the disease is neoplasm.